Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has reported E.P.S. of $2.13 for its third fiscal quarter (ending September 30) versus $-0.26 for the same period a year ago. Relative to the consensus estimate of $0.73, this was a premium of $1.40. E.P.S. were $1.55 for the latest four quarters through September 30 versus $-1.25 for the same period a year ago.
Recent Price Action
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) stock closed at $3.88 on 11/7/19 after a modest gain of 0.8%. NORMAL trading volume accompanied the advance. The stock has been extremely weak relative to the market over the last nine months but has risen 1.0% during the last week.
Current PriceTarget Research Rating
LXRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
LXRX is currently unrated.
The stock is currently unrated.